Phase II study of sunitinib in tumors with c-KIT mutations: results from the NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocol V. (October 2022) - Gien, L.; Song, Z.; Poklepovic, A.; Collisson, E.A.; Mitchell, E.P.; Zweibel, J.A.; Harris, P.; Gray, R.J.; Wang, V.; McShane, L.M.; Rubinstein, L.V.; Patton, D.R.; et al.